ライフサイエンスコーパス: perimenopausal

1 42-52 years, and all were initially pre- or perimenopausal.

2 hese women were postmenopausal, and six were perimenopausal.

3 (mean [SD], 28.26 [5.05] years), 27 women of perimenopausal age (mean [SD] age, 45.21 [3.41] years; i

4 Within the perimenopausal age group, meeting Stages of Reproductive

5 rt of a change in a central biomarker during perimenopausal age that is also present during major dep

6 On average, MAO-A VT in perimenopausal age was elevated by 34% compared with rep

7 antly lower in premenopausal (age 14-44) and perimenopausal (age 45-54) women than in men of the same

8 bar spine and femoral neck were performed in perimenopausal and early postmenopausal women aged 54.9

9 If women are pre- or perimenopausal and have received 5 years of adjuvant tam

10 dence of ovarian cancer occurring during the perimenopausal and immediate postmenopausal periods.

11 oincided to draw increasing attention to the perimenopausal and menopausal years.

12 Participants were perimenopausal and postmenopausal women aged 30 to 89 ye

13 Cases were perimenopausal and postmenopausal women aged 30 to 89 ye

14 ciated with invasive colon cancer risk among perimenopausal and postmenopausal women in the Californi

15 e implications for the choice of hormones in perimenopausal and postmenopausal women.

16 course of estrogen therapy on depression in perimenopausal and postmenopausal women.

17 idlife Health Project and included 17 early (perimenopausal) and continuous users of HT and 17 never

18 Thirteen were premenopausal, four perimenopausal, and 14 postmenopausal by history and hor

19 fat mass, and lean body mass in adolescent, perimenopausal, and elderly women, possibly as the resul

20 hnic cohort of women who were pre- and early perimenopausal at baseline, with multivariable, repeated

21 Both the developing and perimenopausal brain are characterized by a sensitive pe

22 y and premenstrual dysphoria was observed in perimenopausal depressed women.

23 ectly test the estrogen withdrawal theory of perimenopausal depression (PMD).

24 ment of novel pharmacological treatments for perimenopausal depression and related disorders, such as

25 synthesized to describe a heuristic model of perimenopausal depression development.

26 steroids in both premenstrual dysphoria and perimenopausal depression has led to the suggestion that

27 Mood variability in women with perimenopausal depression may reflect episodic alteratio

28 ionship between ovarian function and mood in perimenopausal depression remains unclear.

29 cial environment of midlife to contribute to perimenopausal depression risk.

30 ion with onset in the menopause transition ("perimenopausal depression") involving alterations in str

31 The relevant literature in perimenopausal depression, including prevalence, predict

32 ports of estradiol's therapeutic efficacy in perimenopausal depression, the relationship between ovar

33 dysphoria was an invariant accompaniment of perimenopausal depression.

34 ry-ovarian axis function in women exhibiting perimenopausal depression.

35 strogen, in women who begin treatment in the perimenopausal/early postmenopausal period, whereas rand

36 (fMRI), we examined the long-term impact of perimenopausal HT use on brain function during performan

37 Results indicated that perimenopausal HT users performed better than nonusers o

38 During verbal recognition, perimenopausal HT users showed increased activation in t

39 Premenopausal, but not perimenopausal, Japanese women whose intakes were greate

40 outcomes and intermediate CVD end points in perimenopausal, menopausal, or postmenopausal women.

41 on and content patterns in healthy young and perimenopausal mouse ovaries.

42 Twenty-two depressed women who were either perimenopausal (N=10) or postmenopausal (N=12) received

43 of feeling "blue." The effect of being early perimenopausal on overall dysphoric mood was greatest am

44 Being perimenopausal or postmenopausal compared with being pre

45 rnia Teachers Study (1995-2006) among 56,864 perimenopausal or postmenopausal participants under 80 y

46 e forms of hormone therapy (HT) early in the perimenopausal or postmenopausal stage might confer bene

47 sex-hormone levels during, for example, the perimenopausal or postpartum period appears to heighten

48 , and fluorouracil (CMF; n = 300) in pre- or perimenopausal patients with ER-positive, node-positive

49 The perimenopausal period may be a critical juncture at whic

50 ne therapy when it is initiated early in the perimenopausal period or before the development of signi

51 mes and that starting hormone therapy in the perimenopausal period reduces these outcomes.

52 o an overall dysphoric mood during the early perimenopausal period.

53 enstrual cycle and during the postpartum and perimenopausal periods are associated with increased ris

54 or premenopausal women vs. 0.008 mm/year for perimenopausal/postmenopausal women for AVG IMT; p = 0.0

55 Additionally, among the 160 perimenopausal/postmenopausal women, the intervention sl

56 Women who became early perimenopausal showed a 0.20-kg decline in pinch strengt

57 to ascertain which dietary factors influence perimenopausal skeletal loss.

58 Continuous HT use from the perimenopausal stage versus no use was validated with pr

59 Self-assessment of perimenopausal status had the smallest negative LR (rang

60 Perimenopausal subjects were randomly assigned, double b

61 ts had nearly 3 times the risk of an earlier perimenopausal transition (hazard ratio, 2.7; 95% confid

62 Depression often accompanies the perimenopausal transition and it often precedes overt sy

63 scores >8) had twice the risk of an earlier perimenopausal transition.

64 round the Nation, a prospective study of the perimenopausal transition.

65 These results suggest that perimenopausal use of HT might confer long-term benefits

66 nondense breasts at mammography, and pre- or perimenopausal vs postmenopausal status for the two youn

67 lts add to the literature by focusing on the perimenopausal weight trajectory and support efforts urg

68 2 clinical scenarios initiating therapy in a perimenopausal woman with hot flashes and discontinuing

69 istent mood symptoms were higher among early perimenopausal women (14.9%-18.4%) than among premenopau

70 ts (83.6% vs. 68.1%; P = 0.051), and pre- or perimenopausal women (87.1% vs. 81.7%; P = 0.057); and b

71 Perimenopausal women (aged 40-55 years, with irregular m

72 0.04 to 0.18; P=0.003), and premenopausal or perimenopausal women (difference, 0.15; 95 percent confi

73 s of testosterone concentrations in pre- and perimenopausal women (i.e., age, menopausal status, body

74 Perimenopausal women (n = 69) were randomly assigned (do

75 ing hormone (FSH) plasma levels of depressed perimenopausal women (N=110) attending a menopause clini

76 on plasma total antioxidant status (TAS) in perimenopausal women after control for other contributin

77 rse community cohort of 3,302 pre- and early perimenopausal women aged 42-52 years who were participa

78 neral density (BMD) in 1056 premenopausal or perimenopausal women aged 45-54 y and forearm bone mass

79 groups of women for whom HT is an indication-perimenopausal women and those soon after menopause who

80 enstrual cycle were examined in 70 depressed perimenopausal women attending a menopause clinic and 35

81 significantly increase blood lead levels in perimenopausal women because of postmenopausal bone mine

82 In a prospective cohort of 696 perimenopausal women enrolled in 2008-2012, we sought to

83 owed 3,302 initially premenopausal and early perimenopausal women from 7 US sites and 5 racial/ethnic

84 soy protein and low iron stores may protect perimenopausal women from oxidative stress.

85 e in a population based cohort study of 1240 perimenopausal women from the UK.

86 for major covariates and confounders, early perimenopausal women had higher odds of irritability, ne

87 Monitoring lipids in perimenopausal women should enhance primary prevention o

88 clinical symptoms and certain recent data in perimenopausal women suggest central nervous system invo

89 It is commonly an incidental finding in perimenopausal women undergoing screening mammography.

90 (OR = 1.6, 95% CI: 0.9, 3.0) and among pre-/perimenopausal women who had a high waist-hip ratio (OR

91 Some perimenopausal women with depression may benefit from sh

92 ne patterns of 572 of the 848 pre- and early-perimenopausal women with evidence of a luteal transitio

93 Pre- or perimenopausal women younger than 50 years who had dense

94 significantly better than film for pre- and perimenopausal women younger than 50 years with dense br

95 Cognition seems to improve in perimenopausal women, possibly because menopausal sympto

96 In perimenopausal women, skeletal lead stores are an import

97 nt to the care of obese women, in particular perimenopausal women, undergoing bariatric surgery.

98 l connectivity relative to premenopausal and perimenopausal women.

99 ve disorders in endocrinologically confirmed perimenopausal women.

100 is an effective treatment of depression for perimenopausal women.

101 rption was estimated in 142 healthy pre- and perimenopausal women.

102 with isoflavones on bone or bone turnover in perimenopausal women.

103 ttenuated bone loss from the lumbar spine in perimenopausal women.

104 total BF and percentage BF than did pre- and perimenopausal women.

105 nding a menopause clinic and 35 nondepressed perimenopausal women.

106 likely play a role in the CV risk profile of perimenopausal women.

107 d Japanese) sample of 3297 premenopausal and perimenopausal women.

108 phically dense breasts, and premenopausal or perimenopausal women.

109 pituitary insensitivity to estrogen in aging perimenopausal women.

110 ER+PR+ breast cancer, especially among pre-/perimenopausal women.

111 and mild depressive symptoms experienced by perimenopausal women.

112 acy of a clinical examination in identifying perimenopausal women.These women should be counseled abo